Clinical Outcomes of Reperfusion Therapies in Elderly Patients with Acute Ischemic Stroke

G.G. Sahakyan, M.H. Orduyan, A.G. Babayan, H. Manvelyan
{"title":"Clinical Outcomes of Reperfusion Therapies in Elderly Patients with Acute Ischemic Stroke","authors":"G.G. Sahakyan, M.H. Orduyan, A.G. Babayan, H. Manvelyan","doi":"10.56936/18290825-2022.16.4-102","DOIUrl":null,"url":null,"abstract":"Stroke remains the major cause of disability and mortality worldwide. The incidence of ischemic stroke increases with age and is particularly high in people aged ≥80 years. This study aimed to evaluate the efficacy and safety of reperfusion therapies (intravenous thrombolysis, endovascular thrombectomy, intravenous thrombolysis+ endovascular thrombectomy) in acute ischemic stroke patients aged over 80 years in one of the largest comprehensive stroke centers in Armenia. The study was based on retrospective analyses of prospectively gathered data from all stroke patients of Astghik medical center benefiting reperfusion therapies from 1 February 2021 to 30 April 2022. The safety was evaluated by assessing in-hospital complications and in-hospital and 3-months mortality rates. The efficacy was defined as neurological improvement at discharge and a modified Rankin scale 0-2 (or a return to at least the pre-stroke modified Rankin scale) at 3 months. A total of 216 patients with acute ischemic stroke were treated with reperfusion therapies. The number of patients aged 80 years or over was 41(18,9%). The study group had a mortality rate of 9,7% in an in-hospital setting and 22% at 3 months. Symptomatic intracranial hemorrhage was detected in 3 cases (7.3%). None of the patients developed aspiration pneumonia. 32 patients (78%) had neurological improvement at discharge and 21 patients (51%) were independent or regained pre-stroke activities at 3 months. Based on our results we support the wider application of reperfusion therapies in this age group to reduce disability and improve post-stroke outcomes.","PeriodicalId":353660,"journal":{"name":"THE NEW ARMENIAN MEDICAL JOURNAL","volume":"66 10 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"THE NEW ARMENIAN MEDICAL JOURNAL","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.56936/18290825-2022.16.4-102","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Stroke remains the major cause of disability and mortality worldwide. The incidence of ischemic stroke increases with age and is particularly high in people aged ≥80 years. This study aimed to evaluate the efficacy and safety of reperfusion therapies (intravenous thrombolysis, endovascular thrombectomy, intravenous thrombolysis+ endovascular thrombectomy) in acute ischemic stroke patients aged over 80 years in one of the largest comprehensive stroke centers in Armenia. The study was based on retrospective analyses of prospectively gathered data from all stroke patients of Astghik medical center benefiting reperfusion therapies from 1 February 2021 to 30 April 2022. The safety was evaluated by assessing in-hospital complications and in-hospital and 3-months mortality rates. The efficacy was defined as neurological improvement at discharge and a modified Rankin scale 0-2 (or a return to at least the pre-stroke modified Rankin scale) at 3 months. A total of 216 patients with acute ischemic stroke were treated with reperfusion therapies. The number of patients aged 80 years or over was 41(18,9%). The study group had a mortality rate of 9,7% in an in-hospital setting and 22% at 3 months. Symptomatic intracranial hemorrhage was detected in 3 cases (7.3%). None of the patients developed aspiration pneumonia. 32 patients (78%) had neurological improvement at discharge and 21 patients (51%) were independent or regained pre-stroke activities at 3 months. Based on our results we support the wider application of reperfusion therapies in this age group to reduce disability and improve post-stroke outcomes.
老年急性缺血性脑卒中再灌注治疗的临床疗效分析
中风仍然是全世界致残和死亡的主要原因。缺血性脑卒中的发病率随着年龄的增长而增加,在≥80岁的人群中尤其高。本研究旨在评价再灌注治疗(静脉溶栓、血管内取栓、静脉溶栓+血管内取栓)在亚美尼亚最大的综合性脑卒中中心治疗80岁以上急性缺血性脑卒中患者的疗效和安全性。该研究基于对Astghik医疗中心从2021年2月1日至2022年4月30日接受再灌注治疗的所有脑卒中患者前瞻性收集数据的回顾性分析。通过评估院内并发症和院内及3个月死亡率来评估安全性。疗效定义为出院时神经系统改善和3个月时修改的Rankin量表0-2(或至少恢复到卒中前修改的Rankin量表)。216例急性缺血性脑卒中患者接受再灌注治疗。80岁及以上患者41例(18.9%)。研究组的住院死亡率为9.7%,3个月死亡率为22%。有症状性颅内出血3例(7.3%)。所有患者均未发生吸入性肺炎。32例患者(78%)在出院时神经系统改善,21例患者(51%)在3个月时独立或恢复卒中前活动。基于我们的研究结果,我们支持在这一年龄组更广泛地应用再灌注治疗,以减少残疾和改善卒中后预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信